66 related articles for article (PubMed ID: 18691546)
1. The ever-lengthening arm of p53.
Evan GI
Cancer Cell; 2008 Aug; 14(2):108-10. PubMed ID: 18691546
[TBL] [Abstract][Full Text] [Related]
2. The cytoplasmic side of p53's oncosuppressive activities.
Comel A; Sorrentino G; Capaci V; Del Sal G
FEBS Lett; 2014 Aug; 588(16):2600-9. PubMed ID: 24747877
[TBL] [Abstract][Full Text] [Related]
3. Mdm2: p53's lifesaver?
Shmueli A; Oren M
Mol Cell; 2007 Mar; 25(6):794-6. PubMed ID: 17386256
[TBL] [Abstract][Full Text] [Related]
4. Biological significance of a small highly conserved region in the N terminus of the p53 tumour suppressor protein.
Liu WL; Midgley C; Stephen C; Saville M; Lane DP
J Mol Biol; 2001 Nov; 313(4):711-31. PubMed ID: 11697899
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical study of microvessel density, CD44 (standard form), p53 protein and c-erbB2 in gallbladder carcinoma.
Kalekou H; Miliaras D
J Gastroenterol Hepatol; 2004 Jul; 19(7):812-8. PubMed ID: 15209630
[TBL] [Abstract][Full Text] [Related]
6. [Expression of adhesive molecule CD44v6 and p53 gene in breast cancer tissues and its relation with DNA ploidy].
Zuo WS; Wei L; Wang XW; Wang YS; Yu ZY
Ai Zheng; 2004 Nov; 23(11 Suppl):1418-22. PubMed ID: 15566648
[TBL] [Abstract][Full Text] [Related]
7. Too much of a good thing: the Prl-3 in p53's oyster.
Hinds PW
Mol Cell; 2008 May; 30(3):260-1. PubMed ID: 18471970
[TBL] [Abstract][Full Text] [Related]
8. The ASPP proteins complex and cooperate with p300 to modulate the transcriptional activity of p53.
Gillotin S; Lu X
FEBS Lett; 2011 Jun; 585(12):1778-82. PubMed ID: 21513714
[TBL] [Abstract][Full Text] [Related]
9. Modulation of glucose metabolism by CD44 contributes to antioxidant status and drug resistance in cancer cells.
Tamada M; Nagano O; Tateyama S; Ohmura M; Yae T; Ishimoto T; Sugihara E; Onishi N; Yamamoto T; Yanagawa H; Suematsu M; Saya H
Cancer Res; 2012 Mar; 72(6):1438-48. PubMed ID: 22293754
[TBL] [Abstract][Full Text] [Related]
10. Reactive oxygen species-mediated p53 core-domain modifications determine apoptotic or necrotic death in cancer cells.
Gogna R; Madan E; Kuppusamy P; Pati U
Antioxid Redox Signal; 2012 Mar; 16(5):400-12. PubMed ID: 22145567
[TBL] [Abstract][Full Text] [Related]
11. Essential Roles of E3 Ubiquitin Ligases in p53 Regulation.
Sane S; Rezvani K
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28218667
[TBL] [Abstract][Full Text] [Related]
12. The significance of CD44 expression in gastrointestinal neuroendocrine tumors.
Lai CH; Shan YS; Sy ED; Hsieh YH; Tsai HW; Lee JC; Lin PW
Hepatogastroenterology; 2005; 52(64):1071-6. PubMed ID: 16001632
[TBL] [Abstract][Full Text] [Related]
13. The p53/microRNA network in cancer: experimental and bioinformatics approaches.
Hünten S; Siemens H; Kaller M; Hermeking H
Adv Exp Med Biol; 2013; 774():77-101. PubMed ID: 23377969
[TBL] [Abstract][Full Text] [Related]
14. CD44 isoforms expression in intraductal and invasive pancreatic cancer and its correlation to p53 gene mutations.
Tomaszewska R; Nowak K; Stachura J
Pol J Pathol; 1999; 50(3):145-53. PubMed ID: 10624116
[TBL] [Abstract][Full Text] [Related]
15. p53's double life: transactivation-independent repression of homologous recombination.
Bertrand P; Saintigny Y; Lopez BS
Trends Genet; 2004 Jun; 20(6):235-43. PubMed ID: 15145576
[TBL] [Abstract][Full Text] [Related]
16. Down-regulation of LATS kinases alters p53 to promote cell migration.
Furth N; Bossel Ben-Moshe N; Pozniak Y; Porat Z; Geiger T; Domany E; Aylon Y; Oren M
Genes Dev; 2015 Nov; 29(22):2325-30. PubMed ID: 26588988
[TBL] [Abstract][Full Text] [Related]
17. Understanding p53: new insights into tumor suppression.
Kawauchi K; Wolf SJ
Expert Rev Anticancer Ther; 2014 Oct; 14(10):1101-3. PubMed ID: 25119697
[TBL] [Abstract][Full Text] [Related]
18. Binding of cellular proteins to a conformational domain of tumor suppressor protein p53.
Maxwell SA; Roth JA
Oncogene; 1993 Dec; 8(12):3421-6. PubMed ID: 8247546
[TBL] [Abstract][Full Text] [Related]
19. Hsp70 interactions with the p53 tumour suppressor protein.
Zylicz M; King FW; Wawrzynow A
EMBO J; 2001 Sep; 20(17):4634-8. PubMed ID: 11532927
[No Abstract] [Full Text] [Related]
20. Multiple lysine mutations in the C-terminus of p53 make it resistant to degradation mediated by MDM2 but not by human papillomavirus E6 and induce growth inhibition in MDM2-overexpressing cells.
Nakamura S; Roth JA; Mukhopadhyay T
Oncogene; 2002 Apr; 21(16):2605-10. PubMed ID: 11971195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
